Table 2.
Patient characteristics at start of Glofitamab therapy.
| Patient Characteristics | ||
|---|---|---|
| Age at glofitamab therapy, median (range) | 66 | (41–75) |
| Time from diagnosis to glofitamab, months, median (range) | 45 | (9–284) |
| Previous therapy lines before glofitamab, median (range) | 3 | (2–7) |
| Anti CD-20 therapies before glofitamab, median (range) | 3 | (1–6) |
| Previous autologous stem cell transplantation, n (%) | 5 | (56%) |
| Previous CAR T cell therapy, n (%) | 9 | 100% |
| tisagenlecleucel, n (%) | 6 | 67% |
| axicabtagene ciloleucel, n (%) | 3 | 33% |
| CAR T toxicities, n (%) | ||
| CRS | 6 | 67% |
| Neurotoxicity | 2 | 22% |
| Best response to CAR T cell therapy, n (%) | ||
| SD | 1 | 11% |
| PR | 6 | 67% |
| CR | 2 | 22% |
| Interval CAR T-cell infusion to glofitamab, days, median (range) | 187 | (86–655) |
| Peak expansion of CAR T cells, copies/μg DNA, median (range) | 3260 | (54–12,578) |
| CAR T cell expansion before glofitamab, copies/μg DNA, median (range) | 34 | (0–1470) |
| Patients without detectable CAR T cells before glofitamab, n (%) | 3 | 33% |
| Bulky disease, n (%) | 2 | 22% |
| CNS infiltration, n (%) | 1 | 11% |
| B symptoms, n (%) | 3 | 33% |
CAR T: Chimeric antigen receptor T-cells; CRS: Cytokine release syndrome; SD: Stable disease; PR: Partial response; CR: Complete response; CNS: Central nervous system.